Position in ARVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,315,348
-$1,877,849 QoQ
Shares Held
158,285
-47.5% QoQ
Ownership
0.242%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#48
of 198 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Susquehanna Portfolio Strategies, LLC holds $399,265,861 across 121 Biotechnology names. ARVN ranks #59 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
90,928 | $45,166,665 | |
| 2 | MRNA |
Moderna, Inc.
|
471,043 | $32,987,141 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
211,017 | $18,347,928 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
226,869 | $16,897,203 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
273,562 | $15,653,217 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
166,503 | $13,032,189 | |
| 7 | EXEL |
Exelixis, Inc.
|
229,749 | $12,500,643 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
22,003 | $11,814,510 |
All Filings in ARVN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,315,348 | 158,285 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,193,197 | 301,245 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,572,765 | 301,245 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,331,881 | 273,695 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||